Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926637 · ClinicalTrials.gov registry record
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 3,073
- Enrollment target
NCT03926637: Clinical Trial study, sponsored by Biogen.
NCT03926637 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 3,073 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03926637 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 3,073 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
Interventions
- OTHER Multiple Sclerosis Performance Test (MSPT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,073 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2022-12-05 |
Why NCT03926637 stopped before completion
NCT03926637 is an observational study that tracks outcomes without assigning an intervention. Its 3,073 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Multiple Sclerosis Performance Test (MSPT) is the first listed.
NCT03926637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03926637 about?
NCT03926637 is a clinical study titled "Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis". The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
What is the current status of trial NCT03926637?
This trial is currently terminated. The enrollment target is 3,073 participants. The study started on 2019-06-17. Estimated completion is 2022-12-05.
What interventions are being tested in trial NCT03926637?
The interventions under investigation include: Multiple Sclerosis Performance Test (MSPT) (OTHER).
Who is sponsoring clinical trial NCT03926637?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI